• Account Access
  • Contact Us

    Pre-Sales Support

    Mutual Funds and ETFs - 800-456-7526
    Monday-Thursday: 8:00 a.m. – 6:00 p.m. ET
    Friday: 8:00 a.m. – 5:00 p.m. ET

    ETF Trading Support - 415-315-6600
    Monday-Friday: 9:30 a.m. – 5:00 p.m. ET

    Post-Sales and Website Support
    Monday-Friday: 9:00 a.m. - 6:00 p.m. ET

  • Advisor Log In

Hartford Healthcare HLS Fund


Explore Another ETFs


Seeks long-term capital appreciation.


A stock fund that invests in health care, a sector that is experiencing innovations and breakthroughs across multiple subsectors.

Effective 12/31/17, this Fund is closed to certain qualified pension and retirement plans.  For more information, please refer to the fund's statutory prospectus.

More About Healthcare HLS Fund 


Performance (%)
% (as of 4/30/2020)
Average Annual Total Returns % (as of 4/30/2020)
Hartford Healthcare HLS  IA -1.31 18.22 11.16 8.79 15.61 12.23
Benchmark -1.73 14.07 12.08 9.14 14.86 ---
Morningstar Health Category -1.85 13.25 10.50 6.62 14.04 ---
Performance (%)
% (as of 3/31/2020)
Average Annual Total Returns % (as of 3/31/2020)
Hartford Healthcare HLS  IA -13.48 1.44 6.93 5.46 13.65 11.54
Benchmark -12.90 -1.51 8.25 6.20 13.12 ---
Morningstar Health Category -13.80 -3.66 6.71 3.28 12.64 ---
SI = Since Inception. Fund Inception: 05/01/2000
Operating Expenses:   Net  0.92% |  Gross  0.92%

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted.

Prior to 4/1/2016, the Fund's benchmark was the S&P North American Health Care Sector Index.

IA-Share Morningstar Ratings
(as of 4/30/2020)
  • Overall
    Overall, 4 stars, 3-Year, 3 stars, 5-Year, 4 stars, and 10-Year, 4 stars, rated against 136, 136, 125 and 105 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures. Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
    ©2020 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
  • 136 Products | Health Category
Based on Risk-Adjusted Returns
Calendar Year Returns (%)
Fund Benchmark
2019 33.95 20.87
2018 -2.67 6.71
2017 22.26 22.47
2016 -8.39 -2.05
2015 13.21 7.41
2014 27.39 24.79
2013 51.84 42.19
2012 20.62 18.35
2011 8.54 11.88
2010 7.10 5.20

Excludes sales charges. If sales charges and taxes had been included, the value would have been lower.

CharacteristicsAllocations, exposures and holdings are subject to change. Percentages may be rounded.

Allocations, exposures and holdings are subject to change. Percentages may be rounded.
As of Date 4/30/2020
Net Assets $207 million
# of Holdings 107
% in Equities 98
% in Foreign Equities 17
Beta (3 year) 1.08
R Squared (3 year) 0.88
Standard Deviation 17.92%
Turnover (3/31/2020) 42%
Active Share 57%
Holdings Characteristics
(as of 4/30/2020)
Fund S&P Composite 1500 Health Care Index
Price/Earnings 35.5x 15.0x
Price/Book 4.7x 4.4x
EPS Growth Rate 10.0% 9.2%
Return on Equity 3.5% 22.3%
Asset Weighted Market Cap (billions) $81.8 $137.7
Median Market Cap (billions) $4.7 $3.9

Subsector Exposure

(as of 4/30/2020)
label currentpercentage
Medical Technology 30
Biopharma Large Cap 23
Health Care Services 21
Biopharma Mid Cap 15
Biopharma Small Cap 10
(as of 3/31/2020)
label currentpercentage
Medical Technology 32
Biopharma Large Cap 24
Health Care Services 18
Biopharma Mid Cap 18
Biopharma Small Cap 9
Based on sub-adviser's classification of health care subsectors, which includes combining biotechnology and pharmaceuticals in terms of capitalization: biopharma small-cap, biopharma mid-cap, and biopharma large-cap. Excludes cash. May not total to 100% due to rounding.

Top Holdings

(as of 4/30/2020)
label percentageholding
UnitedHealth Group, Inc. 8.05
Pfizer, Inc. 5.94
Bristol-Myers Squibb Co. 4.05
Eli Lilly & Co. 4.05
Thermo Fisher Scientific, Inc. 3.62
Medtronic plc 3.45
AstraZeneca plc 2.78
Danaher Corp. 2.70
Boston Scientific Corp. 2.62
Edwards Lifesciences Corp. 2.58
Total Portfolio % 39.84
(as of 3/31/2020)
label percentageholding
Pfizer, Inc. 5.16
Bristol-Myers Squibb Co. 4.19
Eli Lilly & Co. 4.10
Medtronic plc 3.60
Thermo Fisher Scientific, Inc. 3.46
UnitedHealth Group, Inc. 2.90
Vertex Pharmaceuticals, Inc. 2.69
AstraZeneca plc 2.68
Danaher Corp. 2.58
Boston Scientific Corp. 2.57
Total Portfolio % 33.93
Market Cap Distribution %
(as of 4/30/2020)
Less than $2 billion 11
$2 billion - $5 billion 12
$5 billion - $10 billion 9
Greater than $10 billion 68
Not Classified 0
Fund Essentials
Inception Date 05/01/2000
Symbol HIAHX
CUSIP 416528719
Fund Number 2055



Coronavirus Update Center 

Collected insights on the impact of coronavirus.

The Future of Healthcare 

Medical technology innovations are disrupting traditional markets and changing the way providers and patients approach healthcare.

Investable Innovation: Tracking Remarkable Biopharmaceutical Advances 

In the coming decade, we should witness the arrival of a host of wonderful new drugs and novel treatment modalities.


Financial Professionals:

Log in to order forms and literature and manage your subscriptions.

  • Add to favorite(0)
  • Email(0)
  • Add to Cart(0)

Fund Literature

Select All

0 items Selected
My Favorites
Please select at least one item.



Expanded Commentary

03/31/2020 | pdf

Current quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund.

Add to

Summary Prospectus

05/01/2019 | pdf

A concise summary of the Fund’s investment strategy, performance, expenses, risks, and management team.

Semi Annual Report

12/02/2019 | pdf

A semi-annual update on the Fund that includes a manager discussion of the Fund’s performance and financial statements.

Statutory Prospectus

05/01/2020 | pdf

An annual update on the Fund that includes information about the Fund’s investment manager, sub-adviser, and operations.

Annual Report

12/31/2019 | pdf

An annual update on the Fund that includes a manager discussion of the Fund’s performance and financial statements.


05/01/2020 | pdf

A supplementary document to the Fund’s prospectus that includes additional information about the Fund and its operations.

Important Risks: Investing involves risk, including the possible loss of principal. Security prices fluctuate in value depending on general market and economic conditions and the prospects of individual companies. • Risks of focusing investments on the healthcare related sector include regulatory and legal developments, patent considerations, intense competitive pressures, rapid technological changes, potential product obsolescence, and liquidity risk. • Small- and mid-cap securities can have greater risks and volatility than large-cap securities. • Foreign investments may be more volatile and less liquid than U.S. investments and are subject to the risk of currency fluctuations and adverse political and economic developments. These risks may be greater for investments in emerging markets.

Hartford HLS Funds are distributed by Hartford Funds Distributors, LLC (HFD), Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC (HFMC). The Funds are sub-advised by Wellington Management Company LLP, which is not affiliated with HFD or HFMC.